During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their ...

Cytokinetics said on Tuesday its experimental heart disease drug significantly improved patients' ability to exercise compared to standard-of-care treatment in a late-stage study, sending shares of ...